Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ:DMII) — Market Cap & Net Worth
Market Cap & Net Worth: Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII)
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ:DMII) has a market capitalization of $647.19 Million ($647.19 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10967 globally and #2871 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Drugs Made In America Acquisition II Corp. Ordinary Shares's stock price $10.17 by its total outstanding shares 63700000 (63.70 Million). Also see Drugs Made In America Acquisition II Cor assets under control for a full breakdown of the balance sheet.
Drugs Made In America Acquisition II Corp. Ordinary Shares Market Cap History: 2025 to 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares's market capitalization history from 2025 to 2026. Data shows growth from $630.63 Million to $647.83 Million (0.00% CAGR). Also see cash flow conversion of Drugs Made In America Acquisition II Cor for how efficiently the company converts equity into cash flow.
Drugs Made In America Acquisition II Corp. Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Drugs Made In America Acquisition II Corp. Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Drugs Made In America Acquisition II Cor stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DMII by Market Capitalization
Companies near Drugs Made In America Acquisition II Corp. Ordinary Shares in the global market cap rankings as of September 17, 2026. Review tangible equity quality of Drugs Made In America Acquisition II Cor to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Drugs Made In America Acquisition II Corp. Ordinary Shares by market ranking:
- Twenty One Capital, Inc. (NYSE:XXI): Ranked #6424 globally with a market cap of $1.86 Billion USD.
- Ares Acquisition Corporation II (NYSE:AACT): Ranked #11436 globally with a market cap of $587.05 Million USD.
- Voyager Acquisition Corp (NASDAQ:VACH): Ranked #11848 globally with a market cap of $541.25 Million USD.
- HCM II Acquisition Corp. Unit (NASDAQ:HONDU): Ranked #12012 globally with a market cap of $525.00 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #6424 | Twenty One Capital, Inc. | NYSE:XXI | $1.86 Billion | $5.38 |
| #11436 | Ares Acquisition Corporation II | NYSE:AACT | $587.05 Million | $9.49 |
| #11848 | Voyager Acquisition Corp | NASDAQ:VACH | $541.25 Million | $24.79 |
| #12012 | HCM II Acquisition Corp. Unit | NASDAQ:HONDU | $525.00 Million | $21.00 |
Drugs Made In America Acquisition II Corp. Ordinary Shares Historical Marketcap From 2025 to 2026
Between 2025 and today, Drugs Made In America Acquisition II Corp. Ordinary Shares's market cap moved from $630.63 Million to $ 647.83 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $647.83 Million | +2.73% |
| 2025 | $630.63 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Drugs Made In America Acquisition II Corp. Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $647.19 Million USD |
| MoneyControl | $647.19 Million USD |
| MarketWatch | $647.19 Million USD |
| marketcap.company | $647.19 Million USD |
| Reuters | $647.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp… Read more